Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study

详细信息    查看全文

• 作者：Ralf A. Linker ; Guillaume Wendt
• 关键词：Disease ; modifying treatment ; Fingolimod ; Multiple sclerosis ; Real ; world evidence
• 刊名：Neurology and Therapy
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：5
• 期：2
• 页码：193-201
• 全文大小：453KB
• 刊物主题：Internal Medicine; Neurology;
• 出版者：Springer Healthcare
• ISSN：2193-6536
• 卷排序：5

文摘

IntroductionFingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence of rare and asymptomatic self-limited atrioventricular (AV) blocks. This German non-interventional clinical study aimed to assess the cardiac safety profile in RRMS patients during at least 6 h after the initial treatment or restart after interruption of fingolimod in real-world settings.